V.J. (USA) Medical Management Group 的医学科学专家获Dynacord授权使用首个美国FDA临床3期Exosomes干细胞药的大型药物研究实践。我们在加利福尼亚州洛杉矶和夏威夷檀香山医疗大楼为患者服务，参与代理和使用Exosomes药Dynacord的研究和管理。
The medical science experts of V.J. (USA) Medical Management Group were authorized by Dynacord to use the first large-scale drug research practice of the FDA clinical phase 3 Exosomes stem cell drug. We serve patients at our Orange, California, and Honolulu, Hawaii medical buildings, participating in the research and administration of the agent and use of the Exosomes drug Dynacord.
截止2021年10月Dynacord 已率先获得了FDA第 3 阶段的批准，并为其行业领先的干细胞间充质外泌体（每立方厘米含有 224 亿个细胞）向 FDA 注册了生物药物主文件。
As of October 2021, Dynacord have been the first to receive FDA Phase 3 approval and have bio-registered with the FDA for their industry-leading stem cell mesenchymal exosomes (22.4 billion cells per cubic centimeter).
(Exosomes外泌体是所有细胞释放的小囊泡，尤其是干细胞。从本质上讲它们是携带重要信号蛋白和遗传信息从一个细胞到另一个细胞的小信使， 它们的主要工作是充当我们所有细胞之间的连接，促进细胞彼此靠近或远离的通信。 Exosomes也是控制细胞输送的唯一管道，可以携带Stem Cell和对症的药物毫无拦阻的进入细胞内进行再生和转化，有指向性的成果，具定向定点治疗的潜能）
(Exosomes are small vesicles released by all cells, especially stem cells. Essentially they are small messengers that carry important signaling proteins and genetic information from one cell to another, their main job is to act as a connection between cells, in other words, exosomes promotes the communication between cells close to or away from each other. Exosomes are also the only channel to control cell transport, which can carry Stem Cell and symptomatic drugs into cells for regeneration and transformation without hindrance and with directional results. Exosomes also have the potential for use in targeted therapy)